Structure-based rationale for interleukin 5 receptor antagonism

Current Pharmaceutical Design

Volumn 14, Issue 12, 2008, Pages 1231-1239

  Ishino, Tetsuya ^a   Harrington, Adrian E ^a   Gopi, Hosahudya ^a   Chaiken, Irwin ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AF 17121; ATLIZUMAB; CD131 ANTIGEN; CYTOKINE RECEPTOR ANTAGONIST; DACLIZUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; INTERLEUKIN 5 RECEPTOR; INTERLEUKIN 5 RECEPTOR ALPHA; MEPOLIZUMAB; RESLIZUMAB; AF17121 PEPTIDE; CYCLOPEPTIDE; IL5RA PROTEIN, HUMAN; INTERLEUKIN 5; MONOCLONAL ANTIBODY;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL MODEL; ASTHMA; BINDING AFFINITY; CELL INFILTRATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CRYSTAL STRUCTURE; DISEASE ASSOCIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; EOSINOPHIL; EOSINOPHILIA; EOSINOPHILIC ESOPHAGITIS; HODGKIN DISEASE; HUMAN; HYDROPHOBICITY; HYPEREOSINOPHILIC SYNDROME; INFLAMMATION; INFLAMMATORY DISEASE; MOLECULAR DYNAMICS; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BLOCKING; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; BINDING SITE; CHEMISTRY; DRUG ANTAGONISM; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY; PROTEIN CONFORMATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES; EOSINOPHILIA; EOSINOPHILS; HUMANS; INTERLEUKIN-5; INTERLEUKIN-5 RECEPTOR ALPHA SUBUNIT; PEPTIDES, CYCLIC; PROTEIN CONFORMATION;

EID: 47149112955     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784246144     Document Type: Review

References (77)

1. Brown MA. Antibody treatments of inflammatory arthritis. Curr Med Chem 2005; 12(25):2943-6.
2. Holgate ST. Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease. Cytokine 2004; 28(4-5):152-7.
3. Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004; 56(6): 864-7.
4. D'Haens G, Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep 2006; 8(6): 506-12.
5. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005; 106(8): 2627-32.
6. Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 2006; 54(9): 2997-3000.
7. Yanofsky SD, Baldwin DN, Butler JH, Holden FR, Jacobs JW, Balasubramanian P, et al. High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries. Proc Natl Acad Sci USA 1996; 93(14): 7381-6.
8. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996; 273(5274): 458-64.
9. Lowman HB, Chen YM, Skelton NJ, Mortensen DL, Tomlinson EE, Sadick MD, et al. Molecular mimics of insulin-likw growth factor 1 (IGF-1) for inhibiting IGF-1: IGF-binding protein interactions. Biochemistry 1998; 37(25): 8870-8.
10. Hummel G, Reineke U, Reimer U. Translating peptides into small molecules. Mol Biosyst 2006; 2(10): 499-508.
11. Plaetinck G, Van der Heyden J, Tavernier J, Fache I, Tuypens T, Fischkoff S, et al. Characterization of interleukin 5 receptors on eosinophilic sublines from human promyelocytic leukemia (HL-60) cells. J Exp Med 1990; 172(3): 683-91.
12. Tavernier J, Devos R, Cornelis S, Tuypena T, Van der Heyden J, Fiers W, et al. A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta-chain shared with the receptor for GM-CSF. Cell 1991; 66(6): 1175-84.
13. England BP, Balasubramanian P, Uings I, Bethell S, Chen MJ, Schatz PJ, et al. A potent dimeric peptide antagonist of interleukin-5 that binds two interleukin-5 receptor alpha chains. Proc Natl Acad Sci USA 2000; 97(12): 6862-7.
14. Barnes PJ. Cytokine modulators for allergic diseases. Curr Opin Allergy Clin Immunol 2001; 1(6): 555-60.
15. Barnes PJ. Corticosteroids, IgE, and atopy. J Clin Invest 2001; 107(3): 265-6.
16. Kay AB, Menzies-Gow A. Eosinophils and interleukin-5: The debate continues. Am J Respir Crit Care Med 2003; 167(12): 1586-7.
17. Ayars G, Altman L, Gleich G, Loegering D, Baker C. Eosinophil- and eosinophil granule-mediated pneumocyte injury. J Allergy Clin Immunol 1985; 76: 595-604.
18. Gleich GJ, Flavahan NA, Fujizawa T, Vanhoutte PM. The eosinophil as a mediator of damage to respiratory epithelium: A model for bronchial hyperreactivity. J Allergy Clin Immunol 1988; 81: 776-81.
19. Levi-Schaffer F, Piliponsky AM. Tryptase, a novel link between allergic inflammation and fibrosis. Trends Immunol 2003; 24(4): 158-61.
20. Munitz A, Levi-Schaffer F. Eosinophils: 'new' roles for 'old' cells. Allergy 2004; 59(3): 268-75.
21. Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol 2004; 113(1): 11-28; quiz 29.
22. Rothenberg ME, Mishra A, Brandt EB, Hogan SP. Gastrointestinal eosinophils. Immunol Rev 2001; 179: 139-55.
23. Yang GY, West AB. What do eosinophils tell us in biopsies of patients with inflammatory bowel disease? J Clin Gastroenterol 2003; 36(2): 93-8.
24. Busse WW, Rosenwasser LJ. Mechanism of asthma. J Allergy Clin Immunol 2003; 111(3 Suppl): S799-804.
25. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002; 359(9317): 1577-8.
26. Woodruff PG, Fahy JV. Asthma prevalence, pathogenesis, and prospects for novel therapies. JAMA 2001; 286(4):395-8.
27. Foster PS, Hogan SP, Yang M, Mattes J, Young IG, Matthaei KI, et al. Interleukin-5 and eosinophils as therapeutic targets for asthma. Trends Mol Med 2002; 8(4): 162-7.
28. Chung KF, van Rensen E, Stirling R, Barnes PJ. IL-5 in asthma. Thorax 2002; 57(8): 751.
29. Sanderson CJ, Urwin D. Interleukin-5: A drug target for allergic diseases. Curr Opin Investig Drugs 2000; 1(4): 435-41.
30. Basten A, Boyer MH, Beeson PB. Mechanism of eosinophilia. I. Factors affecting the eosinophil response of rats to Trichinella spiralis. J Exp Med 1970; 131(6): 1271-87.
31. Wardlaw AJ, Brightling C, Green R, Woltmann G, Pavord I. Eosinophils in asthma and other allergic diseases. Br Med Bull 2000; 56(4): 985-1003
32. Rothenberg ME. Eosinophilia. N Engl J Med 1998; 338(22): 1592-600.
33. Zangrilli J, Robertson N, Shetty A, Wu J, Hastie A, Fish JE, et al. Effect of IL-5, glucocorticoid, and Fas ligation on Bcl-2 homologue expression and caspase activation in circulating human eosinophils. Clin Exp Immunol 2000; 120(1): 12-21.
34. Sehmi R, Denburg JA. Bone marrow in allergic disease: The role of Interleukin-5 as an eosinophilopoietic factor. New York: Marcel Dekker, Inc., 1999.
35. Vaux DL, Lalor PA, Cory S, Johnson GR. In vivo expression of interleukin 5 induces an eosinophilia and expanded Ly-1B lineage populations. Int Immunol 1990; 2(10): 965-71.
36. Dent LA, Strath M, Mellor AL, Sanderson CJ. Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med 1990; 172(5): 1425-31.
37. McKinnon M, Banks M, Solari R, Robertson G. Interleukin-5 and the Interleukin-5 Receptor: Target for Drug Discovery in Asthma. New York: Marcel Dekker, Inc., 1999.
38. Simon D, Braathen LR, Simon HU. Anti-interleukin-5 antibody therapy in eosinophilic diseases. Pathobiology 2005; 72(6): 287-92.
39. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: A pilot study. Am J Respir Crit Care Med 2003; 167(12): 1655-9.
40. Menzies-Gow A, Flood-Page P, Sehmi R, Burman J, Hamid Q, Robinson DS, et al. Anti-EL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 2003; 111(4): 714-9.
41. Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 2004; 113(1):115-9.
42. Chihara J, Plumas J, Gruart V, Tavernier J, Prin L, Capron A, et al. Characterization of a receptor for interleukin 5 an human eosinophils: Variable expression and induction by granulocyte/macrophage colony-stimulating factor. J Exp Med 1990; 172(5): 1347-51.
43. Migita M, Yamaguchi N, Mita S, Higuchi S, Hitoshi Y, Yoshida Y, et al. Characterization of the human IL-5 receptors on eosinophils. Cell Immunol 1991; 133(2):484-97.
44. Carr PD, Gustin SE, Church AP, Murphy JM, Ford SC, Mann DA, et al. Structure: Of the complete extracellular domain of the common beta subunit of the human GM-CSF, IL-3, and IL-5 receptors reveals a novel dimer configuration. Cell 2001; 104(2): 291-300.
45. McClure BJ, Hercus TR, Cambareri BA, Woodcock JM, Bagley CJ, Howlett GJ, et al. Molecular assembly of the ternary granulocyte-macrophage colony-stimulating factor receptor complex. Blood 2003; 101(4): 1308-15.
46. Scibek JJ, Evergren E, Zahn S, Canziani GA, Van Ryk D, Chaiken IM. Biosensor analysis of dynamics of interleukin 5 receptor subunit beta(c) interaction with IL5: IL5R(alpha) complexes. Anal Biochem 2002; 307(2):258-65.
47. Murphy JM, Ford SC, Wiedemann UM, Carr PD, Ollis DL, Young IG. A novel functional epitope formed by domains 1 and 4 of the human common beta-subunit is involved in receptor activation by granulocyte macrophage colony-stimulating factor and interleukin 5. J Biol Chem 2003; 278(12): 10572-7.
48. Milburn MV, Hassell AM, Lambert MH, Jordan SR, Proudfoot AE, Graber P, et al. A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5. Nature 1993; 363(6425): 172-6.
49. Johanson K, Appelbaum E, Doyle M, Hensley P, Zhao B, Abdel-Meguid SS, et al. Binding interactions of human interleukin 5 with its receptor alpha subunit. Large scale production, structural, and functional studies of Drosophila-expressed recombinant proteins. J Biol Chem 1995; 270(16): 9459-71.
50. Morton T, Li J, Cook R, Chaiken I. Mutagenesis in the C-terminal region of human interleukin 5 reveals a central patch for receptor alpha chain recognition. Proc Natl Acad Sci USA 1995; 92(24): 10879-83.
51. Graber P, Proudfoot AE, Talabot F, Bernard A, McKinnon M, Banks M, et al. Identification of key charged residues of human interleukin-5 in receptor binding and cellular activation. J Biol Chem 1995; 270(26): 15762-9.
52. Tavernier J, Tuypens T, Verhee A, Plaetinck G, Devos R, Van der Heyden J. et al. Identification of receptor-binding domains on human interleukin 5 and design of an interleukin 5-derived receptor antagonist. Proc Natl Acad Sci USA 1995; 92(11): 5194-8.
53. Chaiken I, Proudfoot A. Structure of Interleukin-5. New York: Marcel Dekker, Inc., 1999.
54. Wu SJ, Li J, Tsui P, Cook R, Zhang W, Hu Y, et al. Randomization of the receptor alpha chain recruitment epitope reveals a functional interleukin-5 with charge depletion in the CD loop. J Biol Chem 1999; 274(29): 20479-88.
55. Wu SJ, Tambyraja R, Zhang W, Zahn S, Godillot AP, Chaiken I. Epitope randomization redefines the functional role of glutamic acid 110 in interleukin-5 receptor activation. J Biol Chem 2000; 275(10): 7351-8
56. Li, J, Cook R, Doyle ML, Hensley P, McNulty DE, Chaiken I. Monomeric isomers of human interleukin 5 show that 1: 1 receptor recruitment is sufficient for function. Proc Natl Acad Sci USA 1997; 94(13): 6694-9
57. Plugariu CG, Wu SJ, Zhang W, Chaiken I. Multisite mutagenesis of interleukin 5 differentiates sites for receptor recognition and receptor activation. Biochemistry 2000; 39(48): 14939-49.
58. Taniguchi T. Cytokine signaling through nonreceptor protein tyrosine kinases. Science 1995; 268(5208):251-5.
59. Bazam JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990; 87(18): 6934-8.
60. Ishino T, Pasut G, Scibek J. Chaiken I. Kinetic interaction analysis of human interleukin 5 receptor alpha mutants reveals a unique binding topology and charge distribution for cytokine recognition. J Biol Chem 2004; 279(10): 9547-56.
61. Ishino T, Urbina C, Bhattacharya M, Panarello D, Chaiken I. Receptor epitope usage by interleukin 5 mimetic peptide. J Biol Chem 2005; 280: 22951-61.
62. Ishino T, Pillalamarri U, Panarello D, Bhattacharya M, Urbina C, Horvat S, et al. Asymmetric usage of antagonist charged residues drives interleukin-5 receptor recruitment but is insufficient for receptor activation. Biochemistry 2006; 45(4): 1106-15.
63. Ruchala P, Varadi G, Ishino T, Scibek J, Bhattacharya M, Urbina C, et al. Cyclic peptide interleukin 5 antagonists mimic CD turn recognition epitope for receptor alpha. Biopolymers 2004; 73(5): 556-68.
64. Bhattacharya M, Pillalamari U, Sarkhel S, Ishino T, Urbina C, Jameson B, et al. Recruitment pharmacophore for interleukin 5 receptor alpha antagonism. Biopolymers 2007; 88(1): 83-93.
65. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4(11): 1302-7.
66. Lalezari JP, Henry K, O'Hearn M, Moutaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348(22): 2175-85.
67. Moore JP, Doms RW. The entry of entry inhibitors: A fusion of science and medicine. Proc Natl Acad Sci USA 2003; 100(19): 10598-602.
68. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146(5): 707-16.
69. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334(4): 246-54.
70. de Herder WW, Lamberts SW. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol 2002; 14(1): 53-7.
71. Bevan JS. Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005; 90(3): 1856-63.
72. Gopi HN, Tirupula KC, Baxter S, Ajith S, Chaiken IM. Click chemistry on azidoproline: High-affinity dual antagonist for HIV-l envelope glycoprotein gp120. ChemMedChem 2006; 1(1): 54-7.
73. Cocklin S, Gopi H, Querido B, Nimmagadda M, Kuriakose S, Cicala C, et al. Broad-spectrum anti-HIV potential of a peptide HIV-1 entry inhibitor. J Virol 2007; 81: 3645-8.
74. Martinez-Moczygemba M, Huston DP. Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. J Allergy Clin Immunol 2003; 112(4): 653-65; quiz 666.
75. Koradi R, Billeter M, Wuthrich K. MOLMOL: A program for display and analysis of macromolecular structures. J Mol Graph 1996; 14(1): 51-5 29-32.
76. Elkin PA, Christinger HW, Sandowski Y, Sakal E, Gertler A, de Vos AM, et al. Ternary complex between placental lactogen and the extracellular domain of the prolactin receptor. Nat Struct Biol 2000; 7(9): 808-15.
77. Ishino T, Robertsonm N, Chaiken I. In: Litwack G, Ed. Cytokine recognition by human interleukin-5 receptor. Vitamins and hormones. New York: Academic Press 2005; 321-44.